X4 Pharmaceuticals develops orally administered CXCR4 inhibitors, markets mavorixafor (XOLREMDI) in the U.S., and runs global clinical programs in rare immune disorders (WHIM, chronic neutropenia) and oncology.
x4pharma.comPart of: Boston tech scene from Fundable